Moreover, we identified STAT3 activation in a subset of patients with PTEN loss, suggesting that novel strategies to block the STAT3 pathway in combination with trastuzumab treatment may be especially relevant in PTEN- deleted breast cancer. This evidence concerns the gene PTEN and breast carcinoma.